{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:29:06Z","timestamp":1790281746990,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI13C0016"],"award-info":[{"award-number":["HI13C0016"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jaut.2019.03.008","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T10:28:42Z","timestamp":1553509722000},"page":"114-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Soluble siglec-5 is a novel salivary biomarker for primary Sjogren's syndrome"],"prefix":"10.1016","volume":"100","author":[{"given":"Jennifer","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeseon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungYe","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hee","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Hyang","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Shim","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-La","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ki","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyeon","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2019.03.008_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-med-043015-123313","article-title":"Mechanisms and new strategies for primary Sjogren's syndrome","volume":"68","author":"Mavragani","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jaut.2019.03.008_bib2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.03.008_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.21591","article-title":"American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort","volume":"64","author":"Shiboski","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2019.03.008_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.03.008_bib5","doi-asserted-by":"crossref","first-page":"R194","DOI":"10.1186\/ar3523","article-title":"Proteomic analysis of saliva: a unique tool to distinguish primary Sjogren's syndrome from secondary Sjogren's syndrome and other sicca syndromes","volume":"13","author":"Baldini","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.03.008_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.rdc.2016.03.004","article-title":"The proteomics of saliva in Sjogren's syndrome","volume":"42","author":"Katsiougiannis","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.jaut.2019.03.008_bib7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/rheumatology\/kew501","article-title":"Cystatin S-a candidate biomarker for severity of submandibular gland involvement in Sjogren's syndrome","volume":"56","author":"Martini","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.03.008_bib8","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/acr.20289","article-title":"Preclinical validation of salivary biomarkers for primary Sjogren's syndrome","volume":"62","author":"Hu","year":"2010","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2019.03.008_bib9","first-page":"699","article-title":"Cut-off levels of salivary beta2-microglobulin and sodium differentiating patients with Sjogren's syndrome from those without it and healthy controls","volume":"31","author":"Asashima","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.03.008_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5606\/ArchRheumatol.2017.6273","article-title":"Beta-2 microglobulin in whole unstimulated saliva can effectively distinguish between Sjogren's syndrome and non-autoimmune sicca symptoms","volume":"32","author":"Riega-Torres","year":"2017","journal-title":"Arch. Rheumatol."},{"key":"10.1016\/j.jaut.2019.03.008_bib11","series-title":"Janus Kinase 1 Inhibition Suppresses Interferon-Induced B Cell Activating Factor Production in Human Salivary Gland: Potential Therapeutic Strategy for Primary Sjogren's Syndrome","author":"Lee","year":"2018"},{"key":"10.1016\/j.jaut.2019.03.008_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.sbi.2009.06.003","article-title":"Sialic acids as regulators of molecular and cellular interactions","volume":"19","author":"Schauer","year":"2009","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.jaut.2019.03.008_bib13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2019.03.008_bib14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1084\/jem.20131853","article-title":"Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus","volume":"211","author":"Ali","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2019.03.008_bib15","doi-asserted-by":"crossref","first-page":"7765","DOI":"10.1073\/pnas.0510484103","article-title":"Loss of Siglec expression on T lymphocytes during human evolution","volume":"103","author":"Nguyen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jaut.2019.03.008_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000292","article-title":"SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjogren's syndrome","volume":"2","author":"Rose","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2019.03.008_bib17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/annrheumdis-2012-201586","article-title":"IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus","volume":"72","author":"Rose","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.03.008_bib18","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/rheumatology\/kex220","article-title":"Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study","volume":"56","author":"Rose","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.03.008_bib19","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/annrheumdis-2012-202552","article-title":"MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome","volume":"73","author":"Maria","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.03.008_bib20","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.15252\/embj.201591407","article-title":"Immunomodulatory activity of extracellular Hsp 70 mediated via paired receptors Siglec-5 and Siglec-14","volume":"34","author":"Fong","year":"2015","journal-title":"EMBO J."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119300642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119300642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:35:32Z","timestamp":1778546132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841119300642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":20,"alternative-id":["S0896841119300642"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2019.03.008","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble siglec-5 is a novel salivary biomarker for primary Sjogren's syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2019.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}